Patents by Inventor Jonathan Douglas Finn

Jonathan Douglas Finn has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polynucleotides, Compositions, and Methods for Genome Editing
    Publication number: 20240076636
    Abstract: Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.
    Type: Application
    Filed: April 7, 2023
    Publication date: March 7, 2024
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Christian Dombrowski, Jonathan Douglas Finn, Amy Madison Rhoden Smith, Seth C. Alexander
  • Polynucleotides, compositions, and methods for genome editing
    Patent number: 11697806
    Abstract: Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.
    Type: Grant
    Filed: March 24, 2020
    Date of Patent: July 11, 2023
    Assignee: Intellia Therapeutics, Inc.
    Inventors: Christian Dombrowski, Jonathan Douglas Finn, Amy Madison Rhoden Smith, Seth C. Alexander
  • COMPOSITIONS AND METHODS FOR TRANSGENE EXPRESSION FROM AN ALBUMIN LOCUS
    Publication number: 20220354967
    Abstract: The present disclosure is directed to methods and compositions useful for inserting and expressing a heterologous (exogenous) gene within a genomic locus, such as a safe harbor site, of a host cell.
    Type: Application
    Filed: April 16, 2021
    Publication date: November 10, 2022
    Inventors: Jonathan Douglas Finn, Hon-Ren Huang, Moitri Roy, KehDih Lai, Rachel Sattler, Christos Kyratsous, Cheng Wang
  • Modified AAV Capsid Proteins for Treatment of Arthritic Disease
    Publication number: 20220267797
    Abstract: The invention relates to recombinant adeno-associated virus (rAAV) virions for gene therapy, wherein the rAAV virions comprise a novel capsid protein. In particular, the invention relates to the use of such virions in gene therapy for the treatment of an arthritic disease, such as for example rheumatoid arthritis, or symptoms thereof, preferably by intraarticular administration.
    Type: Application
    Filed: July 15, 2020
    Publication date: August 25, 2022
    Inventors: Sabine Maria Gertrude Van Der Sanden, Susanne Anna Snoek, Niels Broekstra, Jonathan Douglas Finn, Dirk Grimm, Kathleen Börner
  • NUCLEIC ACID CONSTRUCTS AND METHODS OF USE
    Publication number: 20210316014
    Abstract: The present disclosure provides bidirectional nucleic acid constructs that allow enhanced insertion and expression of a nucleic acid sequence of interest, e.g., encoding a therapeutic agent such as a polypeptide.
    Type: Application
    Filed: April 16, 2021
    Publication date: October 14, 2021
    Inventors: Jonathan Douglas Finn, Hon-Ren Huang
  • MODIFIED RAAV CAPSID PROTEIN FOR GENE THERAPY
    Publication number: 20200354744
    Abstract: The invention relates to recombinant adeno-associated virus (rAAV) virions for gene therapy, wherein the rAAV virions comprise a novel capsid protein. In particular, the invention relates to the use of such virions in gene therapy for the treatment of an arthritic disease, such as for example rheumatoid arthritis, or symptoms thereof, preferably by intraarticular administration.
    Type: Application
    Filed: January 17, 2019
    Publication date: November 12, 2020
    Inventors: Jonathan Douglas Finn, Dirk Grimm, Kathleen Börner, Niels Broekstra, Susanne Anna Snoek, Sabine Maria Gertrude Van Der Sanden
  • Polynucleotides, Compositions, and Methods for Genome Editing
    Publication number: 20200354702
    Abstract: Compositions and methods for gene editing. In some embodiments, a polynucleotide encoding Cas9 is provided that can provide one or more of improved editing efficiency, reduced immunogenicity, or other benefits.
    Type: Application
    Filed: March 24, 2020
    Publication date: November 12, 2020
    Applicant: Intellia Therapeutics, Inc.
    Inventors: Christian Dombrowski, Jonathan Douglas Finn, Amy Madison Rhoden Smith, Seth C. Alexander